No Data
Analysts Conflicted on These Healthcare Names: Vir Biotechnology (VIR) and Moderna (MRNA)
Vir Biotechnology | 10-Q: Q3 2024 Earnings Report
Vir Biotechnology Price Target Maintained With a $110.00/Share by HC Wainwright & Co.
Vir Biotechnology's Promising Hepatitis Programs and Strategic FDA Alignment Justify Buy Rating
Analysts Have Lowered Expectations For Vir Biotechnology, Inc. (NASDAQ:VIR) After Its Latest Results
Barclays Maintains Vir Biotechnology(VIR.US) With Buy Rating, Maintains Target Price $26
No Data
No Data